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TO THE EDITORLights and Shadows of
Antiplatelet Therapy in
Primary Percutaneous
Coronary InterventionWe have read with great interest the paper written by
Zeymer et al. (1), and the authors should be praised
for the investigation into this relevant issue. Ticlo-
pidine was rapidly displaced by clopidogrel because
the new drug solved the risk of bone marrow aplasia,
and consequently, it became the drug of choice dur-
ing the last decade. After the publication of the
TRITON (Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition With
Prasugrel) and PLATO (Platelet Inhibition and Patient
Outcomes) trials, both the European and American
College of Cardiology/American Heart Association
guidelines recommended the 3 agents in primary
percutaneous coronary intervention (PPCI) with Class I,
Level of Evidence: B, with the comment in the Euro-
pean document that both prasugrel and ticagrelor,
unless contraindicated, should be the ﬁrst-line agents
over clopidogrel. In the present study, Zeymer et al.
randomized 62 subjects to 600 mg of clopidogrel
versus 60 mg of prasugrel scheduled for PPCI, and
because prasugrel achieves a lower platelet reactivity
index, the authors concluded that prasugrel should
be preferred to clopidogrel in PPCI. In our opinion,
there are no doubts about the faster and more
powerful effect in platelet inhibition with prasugrel,
but this fact should not be directly translated
into a recommendation of utilization. Antithrombotic
therapy in acute coronary syndromes (ACS) should
always be dictated by an essential balance between
ischemic and bleeding risks, and we should keep in
mind that the main limitation of the new drugs is
their risk of bleeding. In the TRITON study, although
prasugrel was superior to clopidogrel in the whole
cohort of patients with ST-segment elevation myo-
cardial infarction, the dose of clopidogrel was sub-
optimal and the beneﬁt was due to the patients with
secondary PCI, without signiﬁcant differences in
the subgroup of PPCI (2). In the same way, in the
7,544 patients with ST-segment elevation myocardialinfarction in the PLATO trial, ticagrelor was superior
to clopidogrel in all the endpoints with the exception
of a signiﬁcant increase of cerebrovascular accidents
that ﬁnally placed the p value at a level of 0.07 (3).
We believe that because the guidelines give the
same level of recommendation to the 3 agents, none of
them has demonstrated a deﬁnitive beneﬁt over the
other, and although the new drugs have shown more
powerful effect, there are still shadows in the decision
about the preferred drug. The fact that clopidogrel has
no contraindications and prasugrel is limited in a sig-
niﬁcant percentage of patients (4) could mean that
maybe with the former, we have reached the safest
possible balance between ischemia and bleeding.
Because it has been suggested that the beneﬁts of
ticagrelor in ACS with even a discrete reduction in
mortality and fewer contraindications would be
mediated, not only by P2Y12 antagonism, but also by its
adenosine-like effect (5), maybe we should assume
that in the future, we should focus the research in ACS
on drugs with a well-balanced P2Y12 antagonism but
with an additional way of platelet inhibition.*Iñigo Lozano, MD, PhD
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Therapy in Primary Percutaneous Coronary
InterventionWe thank Lozano et al. for their thoughtful comments
on our ETAMI (Early Thienopyridine Treatment to
Improve Primary PCI in Patients With Acute Myocar-
dial Infarction) trial (1) and fully agree with their
statement that in antithrombotic therapy, there
should always be a balance between efﬁcacy and
safety. Our study has investigated the very acute
phase of primary percutaneous coronary intervention
(PCI) in ST-segment elevation myocardial infarction
(STEMI) in which a faster onset of action of a platelet
inhibition effect is desirable to reduce ischemic com-
plications of the procedure. In the recently published
ATLANTIC (A 30 Day Study to Evaluate Efﬁcacy and
Safety of Pre-hospital vs. In-hospital Initiation of
Ticagrelor Therapy in STEMI Patients Planned for
Percutaneous Coronary Intervention) trial, a very
early initiation of ticagrelor in the pre-hospital phase
leading to clinical relevant difference in platelet in-
hibition 1 h after PCI was associated with a reduction
in stent thrombosis compared with the same loading
dose started on average 31 min later in the hospital (2).
In addition, there are several reports linking inade-
quate platelet inhibition at the time of PCI to ischemic
complications, underscoring the importance of an
effective platelet periprocedural inhibition during
primary PCI (3). In the TRITON (Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing
Platelet Inhibition With Prasugrel) trial, patients with
STEMI have especially beneﬁted from prasugrel
compared with clopidogrel without an increase
in bleeding complications (4). These results were
conﬁrmed by recent reports from real-life experience
of registries. Bleeding complications in TRITON
accumulated over time but were not statistically
different between clopidogrel and prasugrel in the
primary PCI group at 30 days as well as at 15 months
(4). The net clinical beneﬁt was clearly in favor of
prasugrel. The statement about a differential effect of
prasugrel between secondary and primary PCI in
STEMI is not correct, and this reference indicated no
statistical heterogeneity between the 2 groups (4).
This has been now well evaluated, and there is no
signiﬁcant interaction for the primary and secondary
endpoints and a consistent effect of prasugrel acrossall types of PCI performed in STEMI patients (5). The
numerical differences are related to the difﬁculties in
measuring periprocedural MI in primary PCI versus
secondary PCI and not related to the efﬁcacy of
prasugrel (5). The statement about contraindications
against prasugrel majorly relates to patients with prior
stroke, which is present in up to 3% of STEMI patients.
Elderly or patients with low body weight <60 kg might
be treated with the same loading dose of 60 mg and a
lower maintenance dose of 5 mg to reduce bleeding
complications.*Uwe Zeymer, MD
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Therapy Following
Anterior ST-Segment
Elevation Myocardial
InfarctionWe would like to commend LeMay et al. (1) for their
work addressing the important clinical conundrum
of whether to provide triple antithrombotic therapy
(TATT) for patients presenting apical akinesis/
